Company Overview

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

  • Name

    Coloplast A/S

  • CEO

    Mr. Kristian Villumsen

  • Website

    www.coloplast.com

  • Sector

    Health Care Equipment and Supplies

  • Year Founded

    1954

Profile

  • Market Cap

    DKK 206.13B

  • EV

    DKK 229.77B

  • Shares Out

    224.84M

  • Revenue

    DKK 26.3B

  • Employees

    16,019

Margins

  • Gross

    67.52%

  • EBITDA

    30.73%

  • Operating

    27.38%

  • Pre-Tax

    24.02%

  • Net

    18.88%

  • FCF

    5.71%

Returns (5Yr Avg)

  • ROA

    23%

  • ROTA

    49.62%

  • ROE

    62.07%

  • ROCE

    57.48%

  • ROIC

    25.96%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    DKK 911.35

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    DKK 887M

  • Net Debt

    DKK 23.64B

  • Debt/Equity

    1.48

  • EBIT/Interest

    9.13

Growth (CAGR)

  • Rev 3Yr

    11.62%

  • Rev 5Yr

    8.42%

  • Rev 10Yr

    8%

  • Dil EPS 3Yr

    1.09%

  • Dil EPS 5Yr

    2.69%

  • Dil EPS 10Yr

    7.52%

  • Rev Fwd 2Yr

    9.28%

  • EBITDA Fwd 2Yr

    10.58%

  • EPS Fwd 2Yr

    9.41%

  • EPS LT Growth Est

    19%

Dividends

  • Yield

  • Payout

    94.97%

  • DPS

    DKK 21

  • DPS Growth 3Yr

    5.27%

  • DPS Growth 5Yr

    13.81%

  • DPS Growth 10Yr

    11.61%

  • DPS Growth Fwd 2Yr

    1.2%

CPSE:COLO B